Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
Open Access
- 1 April 2003
- journal article
- editorial
- Published by Springer Nature in Breast Cancer Research
- Vol. 5 (2) , 1-5
- https://doi.org/10.1186/bcr574
Abstract
Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metastatic breast tumors and prolongs patient survival. Single-agent Herceptin in patients with HER2-amplified breast tumors also induces a definite objective response and clinical benefit rates, and is well tolerated. These data suggest that Herceptin is an effective first-line single-agent therapy for a predictable cohort of metastatic breast cancers and can therefore be used as a platform for therapeutic discovery against tumors that overexpress HER2.Keywords
This publication has 42 references indexed in Scilit:
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growthOncogene, 2001
- ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial aciniNature Cell Biology, 2001
- Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmissionOncogene, 2001
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225Oncogene, 1999
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyThe International Journal of Cell Cloning, 1998
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988